Skip to main content
TipRanks
Go Ultimate75% OFF

Phathom Pharmaceuticals (PHAT) AI Stock Analysis

608 Followers
PHAT

Phathom Pharmaceuticals

(NASDAQ:PHAT)

Select Model
Rating:50Neutral
Price Target:$5.00â–¼(-5.66% Downside)
Action:reiterated
Date:10/31/26

The score is held back primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and deeply negative equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting these risks, the latest earnings call was notably constructive with reaffirmed guidance, improving profitability trends, and a stated path to durable positive cash flow in 2027; valuation is difficult to assess due to negative earnings.

Positive Factors
Rapid VOQUEZNA GrowthStrong year-over-year and sequential revenue growth shows expanding adoption of VOQUEZNA and improving commercial execution. Continued prescription growth can increase operating leverage, support reinvestment in the GI franchise, and strengthen the company’s position before future competition develops.
Negative Factors
Persistent UnprofitabilityPhathom remains materially unprofitable even as revenue expands, so the business has not yet demonstrated fully sustainable earnings generation. Continued operating and net losses could constrain investment flexibility and leave future profitability dependent on further scale and expense discipline.

Phathom Pharmaceuticals (PHAT) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%PHAT-64.67%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$447.10M
Dividend Yield
―
Average Volume (3M)
1.45M
Price to Earnings (P/E)
-5.1
Beta (1Y)
2.16
Revenue Growth
86.75%
EPS Growth
72.98%
Country
US
Employees
371
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Phathom Pharmaceuticals Business Overview & Revenue Model

Company Description

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive...

How the Company Makes Money

Phathom makes money primarily by commercializing and selling its VOQUEZNA franchise in the United States. Revenue is generated from product sales to customers (typically wholesalers/distributors and other channel partners) who supply pharmacies and h...

Phathom Pharmaceuticals Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:-15.61%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by 71% year-over-year revenue growth, 14% sequential growth, a second consecutive quarter of operating profitability, positive operating cash flow, more than two million prescriptions filled, reaffirmed full-year guidance, and a substantial cash balance. The main challenges were a Q3 gross margin miss, expected higher Q4 gross-to-net discount, gradual access adoption, and litigation concerning VOQUEZNA's exclusivity, but management remained confident in the commercial trajectory, cash outlook, development pipeline, and long-term GI strategy.

Positive Updates

Strong Q3 Revenue Growth and Profitability
Q3 net revenue was $84.7 million, up approximately 71% year over year and 14% sequentially. The company delivered its second consecutive quarter of positive operating profit excluding stock-based compensation, with positive operating profit of $5.8 million, and generated approximately $2.1 million of cash from operations.

Negative Updates

Gross Margin Below Guidance
Q3 gross profit margin was approximately 78%, below the company's guidance. Management attributed the variance to certain one-time charges included in cost of revenues and said it does not see incremental recurring pressure from distribution or fulfillment costs.

Company Guidance

Phathom reiterated full-year 2026 revenue guidance of $310 million-$325 million, expects its full year 2026 gross-to-net discount to come in towards the lower part of its 55%-59% guidance range, continues to anticipate gross margin will be approximately 80%, and maintained cash operating expense guidance, excluding stock-based compensation, of $235 million-$245 million, tracking towards the lower part of that range; it also expects its second consecutive quarter of operating profitability to represent a sustainable pattern going into Q4, including in total for full year 2026 and beyond, and maintained guidance of reaching durable positive cash flow in 2027.

Phathom Pharmaceuticals Financial Statement Overview

Summary

Revenue is growing with very strong gross margins (~83%), but the company remains meaningfully unprofitable (TTM net margin ~-41%) and cash generation is still negative (TTM FCF about -$20.6M). The balance sheet is a major constraint due to deeply negative shareholder equity (about -$348M), despite low latest reported debt.

Income Statement

42Neutral

Balance Sheet

28Negative

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue274.88M175.11M55.25M682.00K00
Gross Profit221.77M152.51M47.28M515.00K-620.00K-521.00K
EBITDA-19.82M-152.50M-261.52M-159.05M-169.80M-136.57M
Net Income-83.00M-221.25M-334.33M-201.59M-197.72M-143.88M
Balance Sheet
Total Assets345.02M259.15M378.32M413.84M164.81M189.43M
Cash, Cash Equivalents and Short-Term Investments184.56M129.97M297.26M381.39M155.38M183.26M
Total Debt167.96M211.80M201.91M139.03M97.07M91.34M
Total Liabilities692.66M697.32M631.90M486.60M239.62M117.28M
Stockholders Equity0-438.17M-253.58M-72.76M-74.81M72.16M
Cash Flow
Free Cash Flow-21.04M-167.00M-266.90M-139.21M-147.57M-148.78M
Operating Cash Flow-20.74M-166.78M-266.77M-137.58M-146.53M-148.46M
Investing Cash Flow-302.00K-229.00K-135.00K-1.63M-1.04M-328.00K
Financing Cash Flow70.44M-288.00K182.77M367.58M120.04M44.71M

Phathom Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price5.30

Price Trends

50DMA6.75Negative
100DMA8.37Negative
200DMA9.90Negative

Market Momentum

MACD-0.35Negative
RSI37.42Neutral
STOCH38.92Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHAT, the sentiment is Negative. The current price of 5.30 is below the 20-day moving average (MA) of 5.83, below the 50-day MA of 6.75, and below the 200-day MA of 9.90, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 38.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHAT.

Phathom Pharmaceuticals Risk Analysis

Phathom Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Phathom Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.An adverse outcome in litigation challenging FDA's recognition of GAIN Act-extended NCE exclusivity for VOQUEZNA tablets, or in related FDA proceedings, could result in earlier generic competition than expected and adversely affect our business.Q3, 2026
2.We and others are subject to ongoing adverse event reporting obligations for our approved products and any failure to comply with these requirements could result in regulatory action that would materially harm our business.Q4, 2025
3.We have ceased to qualify as a smaller reporting company in 2026, and as a result we are subject to increased reporting, compliance and internal control requirements, which may increase our costs and strain management resources.Q4, 2025

Phathom Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PHAT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PHATPHAT50Neutral$430.85M-5.1429.66%―86.75%72.98%
ARDXARDX49Neutral$799.36M-13.89-35.30%―17.57%4.82%
ASMBASMB48Neutral$460.74M27.30-4.40%―80.18%94.20%
ENTAENTA44Neutral$253.10M-3.50-64.32%―-3.56%38.76%
PALIPALI41Neutral$168.90M-4.25-35.60%――94.77%
VNDAVNDA39Underperform$226.76M-0.81-106.94%―8.11%-222.50%

* Healthcare Sector Average

Performance Comparison

-50%0%50%PHATPALIVNDAENTAARDXASMBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PHAT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PHATPhathom Pharmaceuticals, Inc.5.30-9.06-63.09%
PALIPalisade Bio, Inc.0.94-1.40-59.74%
VNDAVanda Pharmaceuticals3.75-1.09-22.52%
ENTAEnanta Pharmaceuticals8.23-3.90-32.15%
ARDXArdelyx Inc3.12-2.43-43.78%
ASMBAssembly Biosciences Inc22.39-14.34-39.04%

Phathom Pharmaceuticals Corporate Events

Business Operations and StrategyLegal Proceedings

Phathom Pharmaceuticals Defends VOQUEZNA FDA Exclusivity Rights

Neutral
Oct 26, 2026

On October 26, 2026, Phathom Pharmaceuticals reported that the U.S. Food and Drug Administration opened a public docket to gather comments on legal and regulatory issues arising from litigation brought by BDR Pharmaceuticals over the FDA’s rejection...

Business Operations and StrategyLegal Proceedings

Phathom Defends VOQUEZNA Exclusivity Amid FDA Lawsuit

Neutral
Oct 23, 2026

On October 23, 2026, Phathom Pharmaceuticals reported that BDR Pharmaceuticals International filed a lawsuit against the U.S. Food and Drug Administration and federal defendants, challenging the agency’s alleged refusal to accept an abbreviated new d...

Business Operations and StrategyProduct-Related Announcements

Phathom Starts Phase 3 VOQUEZNA Trial in NERD

Positive
Sep 29, 2026

On September 29, 2026, Phathom Pharmaceuticals began patient screening in its pHalcon-NERD-302 registrational Phase 3 trial of VOQUEZNA tablets as an as-needed regimen for adults with Non-Erosive GERD. The multicenter, randomized, double-blind study...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026